Gemtuzumab and aspartate aminotransferase increased Patient Reports February 13, 2012

Gemtuzumab Side Effects Report #4978389-4
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Apr 07, 2006. Male patient, 40 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, febrile neutropenia, portal vein thrombosis. Gemtuzumab dosage: unknown. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4979712-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Apr 07, 2006. Male patient, 40 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, febrile neutropenia, portal vein thrombosis. Gemtuzumab dosage: unknown. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #5097855-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from GERMANY on Aug 25, 2006. Female patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood chloride increased, blood fibrinogen increased, blood lactate dehydrogenase increased, blood sodium increased. Gemtuzumab dosage: 10.5 MG INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5097882-X
Gemtuzumab side effect was reported by a Consumer or non-health professional from GERMANY on Aug 25, 2006. Female patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood chloride increased, blood fibrinogen increased, blood lactate dehydrogenase increased, blood sodium increased. Gemtuzumab dosage: 10.5 MG INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE. Patient died.


Gemtuzumab Side Effects Report #4867010-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from NETHERLANDS on Sept 08, 1999. Male patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, cerebral thrombosis. Gemtuzumab dosage: 9 MG/M^2. Patient died.

Gemtuzumab Side Effects Report #4911217-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from AUSTRIA on Jan 22, 2004. Male patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, ascites, aspartate aminotransferase increased, blood lactate dehydrogenase increased, dyspnoea, gamma-glutamyltransferase increased, hepatic steatosis, hypokalaemia, liver function test abnormal. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE, LISINOPRIL, TERAZOSIN, FLUCONAZOLE, VANCOMYCIN, MEROPENEM, METOPROLOL SUCCINATE. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4799898-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from JAPAN on Sept 30, 2005. Female patient, 64 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blast cells present, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, cerebral haemorrhage, disseminated intravascular coagulation, gamma-glutamyltransferase increased, haematocrit decreased. Gemtuzumab dosage: 13.5 MG 1X PER 1 DAY INTRAVENOUS DRIP. During the same period patient was treated with MEROPEN, FUNGIZONE, VANCOMYCIN, MINOPHAGEN C, SOLCOSERYL, PRIMPERAN, FAMOTIDINE, VISCORIN. Patient died.

Gemtuzumab Side Effects Report #4866417-6
Gemtuzumab side effect was reported by a Consumer or non-health professional from JAPAN on Dec 13, 2005. Female patient, 64 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blast cell count increased, blood lactate dehydrogenase increased, c-reactive protein increased, cerebral haemorrhage, chills, gamma-glutamyltransferase increased. Gemtuzumab dosage: 13.5 MG 1X PER 1 DAY. During the same period patient was treated with MEROPEN, FUNGIZONE, VANCOMYCIN, MINOPHAGEN C, SOLCOSERYL, PRIMPERAN, FAMOTIDINE, VISCORIN. Patient died.

Gemtuzumab Side Effects Report #5028048-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from UNITED KINGDOM on Dec 29, 2005. Female patient, 63 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood disorder, diarrhoea, haemoglobin decreased, lethargy, loss of consciousness, lower respiratory tract infection, neutrophil count decreased. Gemtuzumab dosage: unknown. Patient was hospitalized. Patient died.


Gemtuzumab Side Effects Report #4869556-9
Gemtuzumab side effect was reported by a Consumer or non-health professional from AUSTRALIA on Oct 15, 2002. Male patient, 57 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anxiety , aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased, haematocrit decreased, mood altered, platelet count decreased. Gemtuzumab dosage: 11.4 MG ONE TIME PER ONE DOSE INTRAVENOUS; SEE IMAGE. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE, PHENERGAN, HYDROCORTISONE, PREDNISONE, ATENOLOL, FLUCONAZOLE, FOLIC ACID. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5959732-6
Gemtuzumab side effect was reported by a Pharmacist from UNITED STATES on Nov 19, 2008. Female patient, 55 years of age, weighting 185.2 lb, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: abdominal distension, abdominal pain , alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, fatigue, international normalised ratio increased, pyrexia. Gemtuzumab dosage: 17MG IV X 1. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4867127-1
Gemtuzumab side effect was reported by a Physician from SPAIN on Mar 10, 2002. Male patient, 20 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anaemia, anuria, ascites, aspartate aminotransferase increased, blood lactate dehydrogenase increased, condition aggravated, hypocalcaemia, liver disorder. Gemtuzumab dosage: 9 MG/M^2 1X PER 1 DOS INTRAVENOUS. During the same period patient was treated with CIPROFLOXACIN, FLUCONAZOLE. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5807571-9
Gemtuzumab side effect was reported by a Physician from FRANCE on July 04, 2008. Male patient was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, cholelithiasis, gamma-glutamyltransferase increased, jaundice . Gemtuzumab dosage: 5 MG EVERY 1 CYC. During the same period patient was treated with EFFEXOR, ARACYTINE, BACTRIM, TIENAM, DAUNORUBICIN, PANTOPRAZOLE, TAHOR. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #5950509-4
Gemtuzumab side effect was reported by a Physician from FRANCE on Nov 07, 2008. Male patient was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, cholelithiasis, gamma-glutamyltransferase increased, jaundice . Gemtuzumab dosage: 5 MG EVERY 1 CYC. During the same period patient was treated with EFFEXOR, CYTARABINE, BACTRIM, TIENAM, DAUNORUBICIN, PANTOPRAZOLE, TAHOR. Patient was hospitalized. Patient recovered.


Gemtuzumab Side Effects Report #5089444-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from NETHERLANDS on Aug 10, 2006. Female patient, 62 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, ascites, aspartate aminotransferase increased, atrial fibrillation , blood bilirubin increased, candidiasis, fluid retention, hepatic function abnormal. Gemtuzumab dosage: 5.2 MG. During the same period patient was treated with CYTARABINE, ETOPOSIDE, IDARUBICIN, SULFAMETHOXAZOLE, COLISTIN. Patient died.

Gemtuzumab Side Effects Report #6119966-7
Gemtuzumab side effect was reported by a Physician from UNITED KINGDOM on Mar 10, 2009. Female patient was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, protein total increased. Gemtuzumab dosage: 4.65 MG EVERY 1 TOT. Patient recovered.